These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 38010824

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J, Park S, Kim S, Kim SH, Oh YS, Sa YK, Hwang Y, Jang SW, Ihm SH, Choi Y.
    Eur J Prev Cardiol; 2024 Feb 15; 31(3):320-329. PubMed ID: 37798123
    [Abstract] [Full Text] [Related]

  • 4. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, Ren QW, Tse HF, Cheung BY, Yiu KH.
    Cardiovasc Diabetol; 2021 May 07; 20(1):100. PubMed ID: 33962654
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.
    Hu WS, Lin CL.
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep 07; 396(9):1977-1986. PubMed ID: 36881169
    [Abstract] [Full Text] [Related]

  • 6. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chiang FT, Tu YK.
    Eur J Endocrinol; 2023 Jul 20; 189(1):S17-S25. PubMed ID: 37474112
    [Abstract] [Full Text] [Related]

  • 7. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
    Ouyang X, Wang J, Chen Q, Peng L, Li S, Tang X.
    Cardiovasc Diabetol; 2023 May 24; 22(1):124. PubMed ID: 37226247
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. SGLT2 Inhibitors vs GLP-1 Receptor Agonists and Clinical Outcomes in Patients With Diabetes With/Without Atrial Fibrillation.
    Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Yeh YH, Kuo CT, See LC, Lip GYH.
    J Clin Endocrinol Metab; 2024 Sep 16; 109(10):2617-2629. PubMed ID: 38466894
    [Abstract] [Full Text] [Related]

  • 10. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
    Fichadiya A, Quinn A, Au F, Campbell D, Lau D, Ronksley P, Beall R, Campbell DJT, Wilton SB, Chew DS.
    Europace; 2024 Mar 01; 26(3):. PubMed ID: 38484180
    [Abstract] [Full Text] [Related]

  • 11. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
    Bhatia K, Jain V, Gupta K, Bansal A, Fox A, Qamar A, Damman K, Vaduganathan M.
    Eur J Heart Fail; 2021 Jun 01; 23(6):1002-1008. PubMed ID: 33609071
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ismayl M, Abbasi MA, Al-Abcha A, El-Am E, Lundgren S, Goldsweig AM, Anavekar NS.
    Curr Probl Cardiol; 2023 May 01; 48(5):101597. PubMed ID: 36681210
    [Abstract] [Full Text] [Related]

  • 16. Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.
    Täger T, Frankenstein L, Atar D, Agewall S, Frey N, Grundtvig M, Clark AL, Cleland JGF, Fröhlich H.
    Clin Res Cardiol; 2022 Apr 01; 111(4):428-439. PubMed ID: 34498169
    [Abstract] [Full Text] [Related]

  • 17. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
    Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, Li KHC, Tang Y, Wei Y, Tse G, Xia Y.
    Front Endocrinol (Lausanne); 2021 Apr 01; 12():619586. PubMed ID: 33815278
    [Abstract] [Full Text] [Related]

  • 18. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
    Li X, Zhang Q, Zhu L, Wang G, Ge P, Hu A, Sun X.
    Int J Cardiol; 2021 Jun 01; 332():119-126. PubMed ID: 33838152
    [Abstract] [Full Text] [Related]

  • 19. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
    Chen YY, Chang HC, Lin YJ, Chien KL, Hsieh YC, Chung FP, Lin CH, Lip GYH, Chen SA.
    Diabetes Metab Res Rev; 2024 Feb 01; 40(2):e3775. PubMed ID: 38340046
    [Abstract] [Full Text] [Related]

  • 20. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis.
    Cao Y, Li P, Li Y, Han Y.
    ESC Heart Fail; 2022 Jun 01; 9(3):1942-1953. PubMed ID: 35338608
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.